Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on February 14, 2024. The filing reports a significant clinical milestone regarding the Company's CellFX® nsPFA™ 360° Cardiac Catheter.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical event and does not contain financial statements or updated financial data.
Material Changes
The primary material event reported is the successful remapping of the first four patients in the Company's CellFX® nsPFA™ 360° Cardiac Catheter First-In-Human Feasibility Study. This event was announced via a press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the context of the clinical study progress. The report serves to disclose the clinical milestone as an "Other Event" under Item 8.01.
Investor Verification Checklist
- Verify the full details of the press release (Exhibit 99.1) regarding the successful remapping of the first four patients.
- Confirm the specific clinical outcomes and safety data associated with the CellFX® nsPFA™ 360° Cardiac Catheter study.
- Review subsequent filings for any financial impact or updated guidance resulting from this clinical milestone.